EGFR and non-small cell lung carcinoma: In addition, ramucirumab (anti-VEGFR2 antibody) plus osimertinib demonstrated encouraging safety and antitumor activity among EGFR-mutant NSCLC patients in a phase I study (NCT02789345) [202].